HighVista Strategies LLC
BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$380.9M2026 Q3
Positions136
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.27.2%
What Changed This Quarter?
Top Holdings
DBC
Invesco DB Commodity
9.0%
RVMD
Revolution Medicines
2.5%
ABVX
Abivax S.A.
2.3%
PCVX
Vaxcyte
2.1%
GMAB
Genmab A/S
2.1%
RLAY
Relay Therapeutics
1.9%
TNGX
Tango Therapeutics
1.9%
TARS
Tarsus Pharmaceuticals
1.9%
New / Increased
24 new · 48 increased
GMABNEW
Genmab A/S
2.1%
MANENEW
Veradermics
1.7%
CTNMNEW
Contineum Therapeutics
0.8%
UNPNEW
Union Pac
0.8%
UALNEW
United Airls
0.7%
EWTX
Edgewise Therapeutics
1.7%
+76.5%
META
Meta Platforms
0.9%
+288.3%
VRDN
Viridian Therapeutics
1.5%
+70.5%
Reduced / Exited
63 reduced · 35 sold out
AMLX
Amylyx Pharmaceuticals
1.2%
-60.2%
PRAX
Praxis Precision Medicines
0.8%
-63.3%
DFTX
Definium Therapeutics
1.1%
-55.1%
RVMD
Revolution Medicines
2.5%
-31.5%
CYTK
Cytokinetics
0.5%
-63.4%
ALMSEXIT
Alumis
1.3%
MLYSEXIT
Mineralys Therapeutics
0.5%
EYPTEXIT
Eyepoint
0.5%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.